Is Theranos Discontinued? What Happened? Scandal

Theranos began with a simple, powerful idea: a tiny drop of blood, hundreds of tests, and results delivered faster and cheaper than traditional labs. Elizabeth Holmes founded the company in 2003 and pitched a compact analyzer that could sit inside pharmacies and doctor’s offices. By the mid‑2010s, Theranos had become a Silicon Valley sensation. It had a $9 billion valuation, a board full of political heavyweights, and a reputation for being the future of diagnostics.

Behind the scenes, almost none of it worked.

Theranos relied on modified third‑party machines for most of its testing because its own devices struggled with accuracy and reliability. The company kept promoting its technology anyway, signing retail pilots and expanding its footprint while avoiding outside scrutiny. In October 2015, a series of investigative reports began to unravel the story. Journalists found inconsistent data, unapproved devices, and labs that failed basic quality‑control standards. Regulators inspected Theranos’s facilities and cited serious deficiencies.

Retail partners paused their programs. The shine started fading.

By 2016, federal regulators banned Holmes from operating a clinical lab and moved to revoke the company’s Clinical Laboratory Improvement Amendments certificate. The SEC charged Theranos and its executives in 2018 with raising money through exaggerated and false statements. That same year, the company dissolved. Later criminal trials resulted in convictions of both the CEO and the former president.

Not only did Theranos collapse, it became a landmark case in medical‑device governance. It demonstrated how easily hype can outrun science, and how basic standards and independent validation are critical to the process. Revolutionary claims require revolutionary proof, and no amount of branding can replace real data.